Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Lupin launches Lurasidone Hydrochloride in US, targeting $4.2bn bipolar depression market Lupin launches Lurasidone Hydrochloride Tablets in the US, entering a $4.2B bipolar depression market with a full range of strengths. byPallavi MadhirajuFebruary 22, 2023